Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)

home / precision-medicine / frontline-treatment-for-newly-diagnosed-lower-risk-myelodysplastic-syndromes-lr-mds

Panelists discuss how emerging therapies, including luspatercept, are reshaping the front-linefrontline treatment landscape for lower-risk myelodysplastic syndromes (LR-MDS), with a focus on personalized approaches, prognostic scoring, and the improvement of anemia management and patient quality of life.